Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab and Rivoceranib Plus HAIC as Conversion Therapy for Potentially Resectable Intermediate-advanced Hepatocellular Carcinoma: a Multicenter, Open-label, Randomized, Phase 2/3 Study

NCT06796803 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT06796803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06796803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab and Rivoceranib Plus HAIC as Conversion Therapy for Potentially Resectable Intermediate-advanced Hepatocellular Carcinoma: a Multicenter, Open-label, Randomized, Phase 2/3 Study
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Phase 2/3
Overall status
Recruiting
Start date
February 20, 2025
Completion date
February 28, 2030
Enrollment
398 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

potentially resectable hepatocellular carcinoma